|Project Title||Severe Uterine Bleed following Novel Oral Anticoagulants Use: A Propensity Score Matched Analysis|
Thursday, April 18, 2019
This analysis investigates the risk of severe uterine bleed for patients treated with Novel Oral Anticoagulants (NOACs) including Rivaroxaban, Dabigatran, Apixaban, and Warfarin in the Sentinel Distributed Database.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.
novel oral anticoagulant (NOAC)
severe uterine bleed
|Population / Cohort||
October 19, 2010 - September 30, 2015
Sentinel Distributed Database (SDD)
- Vaccines, Blood & Biologics
- Devices and Radiologic Health